Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Who Took Part

The abstract describes 20 volunteers taking part.

By PubMed's age tags, the people studied were children, both men and women.

At the end of each treatment period, participants attended an 8-h evaluation visit, during which they were requested to eat two standardized meals and to drink water ad libitum.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The volunteers were allocated by chance, so the Glucagon group and the comparison group should start out alike.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

Some volunteers received a placebo instead of Glucagon, giving a reference point.

In the crossover set-up each of the volunteers took both Glucagon and the comparison in turn, acting as their own control.

The primary outcome was the total fluid intake (ml) during the evaluation visit.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Healthy Volunteers and Hypoglycemic Agents.

Author keywords: Dulaglutide, GLP-1, Hypophysis, Pituitary and Thirst.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 20 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Endocrine), a journal based in United States.

More context: the Glucagon compound page, all human trials.